Prostate cancer Board decisions

The Board remanded the veteran's claim for service connection of prostate cancer to verify exposure to Agent Orange at Chanute AFB, Illinois.

The veteran's claim for a higher rating for prostate cancer residuals was denied. The claims for a higher rating for adjustment disorder with anxiety and TDIU were remanded.

The Board dismissed claims for higher ratings for diabetic peripheral neuropathy and denied higher ratings for several other conditions. It remanded decisions on TDIU and an effective date for Dependents' Educational Assistance.

The Board denied the veteran's claims for a higher rating for erectile dysfunction and prostate cancer, and an earlier effective date for the increased rating of erectile dysfunction.

The Board has granted service connection for prostate cancer, finding that the Veteran's exposure to contaminated water at Camp Lejeune during his military service is at least as likely as not related to his development of prostate cancer.

The Board remanded the veteran's claims for service connection for prostate cancer, brain cancer, and erectile dysfunction due to incomplete development of evidence regarding exposure to herbicide agents.

The Board remanded the case to obtain a new medical opinion from an oncologist regarding the Veteran's cause of death. The previous opinions did not comply with the Board's instructions.

The appeal for a total disability rating based on individual unemployability (TDIU) has been remanded. The Board will reconsider the claim after obtaining all relevant records.

The veteran's effective date for service connection of prostate cancer was granted as April 16, 2018.

The Veteran's appeal for an increased evaluation to 100 percent for prostate cancer was granted. The Board found that the Veteran's prostate cancer has recurred, manifesting as a malignant neoplasm of the genitourinary system.

The Board has remanded the Veteran's claims for prostate cancer, erectile dysfunction, and PTSD due to outstanding VA treatment records not being obtained.

The Board remanded the claim for service connection of prostate cancer to correct errors in assisting the veteran's claim. The Veteran asserts his prostate cancer is secondary to medications used to treat his service-connected gout disability or due to exposure to trichloroethylene (TCE).

The veteran's prostate cancer rating was increased to 100% from July 27, 2023, to January 27, 2024.

The veteran's claims for service connection for hypertension and prostate cancer with urinary incontinence were granted. The claims for bilateral hearing loss disability, headaches, and mitral valve prolapse were remanded.

The veteran's claim for an earlier effective date for prostate cancer was denied, but the veteran was granted special monthly compensation based on aid and attendance. The claim for service connection for sleep apnea was denied.

The Board remanded the claim for service connection of prostate cancer due to errors in obtaining necessary records and medical opinions.

The Board denied the Veteran's appeal to reinstate a 100 percent rating for prostate cancer residuals and special monthly compensation (SMC) at the statutory housebound rate, effective December 1, 2023.

The Board has remanded the case due to an error in determining Agent Orange exposure, and will inquire if the Veteran was exposed between October 1966 and December 1966.

The Veteran's hypertension and prostate cancer are granted pursuant to the PACT Act.,The remaining claims for PTSD, erectile dysfunction, and service connection on a basis other than the PACT Act are remanded.

The Veteran's service connection claims for diabetes mellitus, prostate cancer, and PTSD have been granted. Diabetes mellitus and prostate cancer are presumed to be related to exposure to herbicides during service in Vietnam. PTSD is denied as there is no verifiable stressor.